BioWorld

May 16, 2011

You're Fired! A Quantitative Analysis of Dissolved Deals

In the first two weeks of this month, pharma firms dissolved four partnerships with biotech companies, continuing a trend that's been troubling the industry. Read More

Is CER the Rx for Personalized Medicine?

Infectious Disease Pipeline Thinner, but Inching Forward

Money Raised Year to Date

Money Raised By Biotech in 2011

Week in Review

Word on the Street

Week in Washington

FDA Approvals in April

Phase I Clinical Trials Update: April 2011

Phase II Clinical Trials Update: April 2011

Phase III Clinical Trials Update: April 2011

American Association for Cancer Research

American College of Cardiology

European Association for the Study of the Liver

Non-U.S. Clinical Trials & Regulatory Actions: April 2011

FDA Submissions, Approvals & Other Actions: April 2011

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...